CS MEDICA Welcomes the Danish Government's Proposal to Make the Pilot Program for Prescription-Based Medicinal Cannabis Permanent

Permanent regulation could pave the way for better access and understanding of CBD's benefits and the diversity of products, as seen in more mature global markets.

CS MEDICA A/S (CSMED), a Danish MedTech company specializing in CBD-infused medical devices, supports the Danish government's proposal to make the Pilot Programme for prescription-based medicinal cannabis permanent. This announced proposal, presented by Minister of the Interior and Health Sophie Løhde, is based on a new evaluation showing a significant increase in redeemed prescriptions, now at their highest level since the program's inception in 2018. 

While the proposal focuses on medicinal cannabis, CS MEDICA sees it as an opportunity to highlight the broader potential of cannabinoids, including CBD-infused medical devices, and to advance public understanding of their unique benefits and regulatory distinctions.

A Permanent Program to Foster Understanding and Trust

This initiative mirrors trends in more mature markets such as Germany and the United States, where regulation has strengthened consumer trust and access to safe cannabinoid treatments. A permanent program in Denmark can further educate the market on cannabinoids, foster a more structured and transparent industry, and ensure patient safety.

"A permanent program is a step forward not only for medicinal cannabis but for the entire cannabinoid market," said Lone Henriksen, CEO of CS MEDICA. "It will drive greater clarity between product categories and highlight the benefits of regulated, evidence-based treatments like ours."

Driving a Regulated Future for Cannabinoids

CS MEDICA has long advocated for stricter regulation to eliminate "grey zones" and prioritize patient safety. The company operates under Medical Device Regulation (MDR) standards, ensuring pharmaceutical-grade safety and efficacy for its CBD-infused treatments, which are accessible without a prescription.

The cannabinoid market can be more clearly categorized:

• CBD-Infused Medical Devices: Products like CS MEDICA's range, classified under MDR standards, target pain relief, autoimmune, and stress-related disorders. These solutions offer the stringency of medical regulation combined with over-the-counter accessibility.
• Medicinal Cannabis: Prescription-based products for chronic conditions requiring physician oversight.
• CBD Cosmetics: Wellness and beautifying solutions with limited science-backed claims and less regulatory stringency than medical devices.

"Regulation benefits everyone—patients, healthcare professionals, and companies, who prioritize compliance and quality," Henriksen added. "This shift will enhance understanding of CBD-infused treatments and their role in providing accessible, science-backed care."

Learning from Global Market Leaders

In mature markets like Germany and the U.S., clear regulations have fostered consumer trust, market growth, and innovation. CS MEDICA expects the Danish government's initiative to drive similar outcomes.

"This proposal will bring needed attention to cannabinoids' benefits and distinctions, promoting responsible use and growth," said Lone Henriksen. "With insights from the pilot program, it's clear patients are ready for these solutions."